CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
- To interpret and address, through clinical and translational research, the disease burden associated with breast cancer both in the adjuvant and the metastatic setting in Canada.
- To review recent developments in the understanding of molecular biology, new therapeutics and clinical trial methodology as these relate to breast cancer.
- To update, review, and discuss recent results of clinical studies conducted by or in collaboration with Canadian Cancer Trials Group.
- To place the results of clinical studies in the context of ongoing care of patients in Canada with breast cancer and to translate these results into clinical practice.
- To provide a learning environment supportive to investigators.
- To provide mentoring opportunities for investigators new to clinical research.

8:00am Welcome & Review of Morning’s Objectives (Feedback, Recognition of centres with high accrual)
8:05am Recognition and Congratulations
8:15am Update: Publications/Abstracts 2017-18
8:25am Update from the IND Committee
8:45am Approved Studies Pending Activation
9:30am Studies Open to Accrual
10:15am Coffee
10:30am News from Closed/Analyzed Studies
10:45am Summary of 2018APR27 Retreat / Potential New Studies
11:30am NCTN Grant Renewal
11:40am Meeting format and Other Business
12:00 Adjournment
Objectives
CCTG Presentations for ASCO / 2017/18 Publications
Update from the IND Committee (Phil Bedard to introduce)
- IND.229 - A Phase 1b Pharmacodynamic Study of Durvalumab (MEDI4736) in Patients with HER-2 Positive Metastatic Breast Cancer (MBC) Receiving Trastuzumab (S. Chia)
- IND.231 - A Phase I/II Study of CX5461 (K. Gelmon/J. Hilton)
- IND.236 - A Phase Ib and Open Label Phase II Study of CFI-402257 in Combination with Weekly Paclitaxel in Patients with Advanced/Metastatic HER2 Negative Breast Cancer (P. Bedard/M. Mates)
- SU2C Planned Trials: (D. Cescon)
  - Single Agent Phase II - Breast
  - Durvalumab Combination – TNBC
  - Single Agent Phase II - TNBC and ER+ post CDK4/6

Approved Studies Pending Activation
- MA.39 - Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (Tim Whelan)
- S1418 - A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (pN1) After Neoadjuvant Chemotherapy (S.Chia)

Studies Open to Accrual
- MA.36 - A Randomised, Double-Blind, Parallel group, Placebo-Controlled Multicenter Phase III Study to Assess the Efficacy and Safety of Olaparib versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy (A. Eisen)
- MA37 (PALLAS - PALbocillob CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Adjuvant Endocrine Therapy versus Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer) (J. Lemieux)
- MAC18 - POSITIVE: A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy (E. Warner)
- MAC.19 - A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1 -3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy (S. Latosinsky)
- MAC.20 - Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (V. Bernstein)
- MAC.33 - A Randomised Phase III Study Of Radiation Doses And Fractionation Schedules For Ductal Carcinoma In Situ (DCIS) Of The Breast (I. Olivotto/T. Whelan)
- MAC.34 (Aphinity) - A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as AdjuvantTherapy in Patients with Operable HER2-Positive Primary Breast Cancer (S. Dent)
- MAC.38 - Randomized Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer (A. Joy)
- MAC.12 - Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial (K. Pritchard)

News from Closed/Analyzed Studies
- MA.32 - A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer (MA.32D remains open to accrual for ER/PgR negative Patients) (P. Goodwin)
- MA.35 - A Randomised Phase III Study Of Radiation Doses And Fractionation Schedules For Ductal Carcinoma In Situ (DCIS) Of The Breast (I. Olivotto/T. Whelan)
- MA.34 (Aphinity) - A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as AdjuvantTherapy in Patients with Operable HER2-Positive Primary Breast Cancer (S. Dent)
- MAC.38 - Randomized Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer (A. Joy)
- MAC.12 - Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial (K. Pritchard)

Summary of 2018APR27 Retreat / Potential New Studies (S. Chia / Tim Whelan)
- Late Recurrences ( D. Cescon/S. Bratman)
- PLK4 monotherapy basket study (D. Cescon)
- TTK inhibitor plus paclitaxel in HER2 negative metastatic breast cancer regardless of ER status (P. Bedard)
- Optimizing Neoadjuvant immunotherapy in TNBC (S. Chia)
- Abemaciclib in ESR-1 mutant metastatic breast cancer ( J. Hilton)
- Abemaciclib after ribociclib failures (S. Chia)

NCTN Grant Renewal (Stephen Chia / Tim Whelan)
Other Business